Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL400674 | 0.83 | EGFR (0.54) | EGFRSMN1; SMN2ALDH1A1MAPK1ACLY | |
| SCHEMBL921287 | 0.83 | EGFR (0.54) | EGFRSMN1; SMN2ALDH1A1MAPK1POLB | |
| SCHEMBL5190356 | 0.82 | POLB (0.52) | EGFRSMN1; SMN2ALDH1A1MAPK1POLB | |
| Hydrochloric Acid SCHEMBL921288 | 0.82 | EGFR (0.53) | EGFRSMN1; SMN2ALDH1A1MAPK1ACLY | |
| SCHEMBL3702546 | 0.81 | SMN1; SMN2 (0.40) | EGFRSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL30436565 | 0.81 | SMN1; SMN2 (0.40) | EGFRSMN1; SMN2ALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL5013614 | 0.80 | PARP1 (0.50) | EGFRSMN1; SMN2ALDH1A1MAPK1POLB | |
| SCHEMBL14469060 | 0.79 | EGFR (0.57) | EGFRSMN1; SMN2ALDH1A1MAPK1ACLY | |
| SCHEMBL10031554 | 0.79 | EGFR (0.47) | EGFRSMN1; SMN2ALDH1A1MAPK1POLB | |
| SCHEMBL10001170 | 0.79 | EGFR (0.47) | EGFRSMN1; SMN2ALDH1A1MAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-9957277-B2 | eIF4A-inhibiting compounds and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170145026-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| CN-101679270-B | Dihydroquinone and dihydronaphthyridine inhibitors of JNK | HOFFMANN LA ROCHE | 2013-05-01 | — | — | CN | disclosed |
| US-8304539-B2 | Fused heteroaryl modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| US-8163906-B2 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | ROCHE PALO ALTO, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163906-B2 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | ROCHE PALO ALTO, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163906-B2 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | ROCHE PALO ALTO, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2148862-B1 | DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK | HOFFMANN LA ROCHE (CH) | 2012-03-28 | — | — | EP | disclosed |
| EP-2148862-B1 | DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK | HOFFMANN LA ROCHE (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-20110002952-A1 | FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kappaB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-06 | — | — | US | disclosed |
| CN-101679270-A | Dihydroquinone and dihydronaphthyridine inhibitors of JNK | HOFFMANN LA ROCHE | 2010-03-24 | — | — | CN | disclosed |
| EP-2148862-A1 | DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK | F. Hoffmann-Roche AG (CH) | 2010-02-03 | — | — | EP | disclosed |
| WO-2009015917-A2 | DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009015917-A2 | DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008138920-A1 | DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008138920-A1 | DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-20 | — | — | WO | disclosed |
| US-20080287458-A1 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | ROCHE PALO ALTO LLC | 2008-11-20 | — | — | US | disclosed |
| US-20080287458-A1 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | ROCHE PALO ALTO LLC | 2008-11-20 | — | — | US | disclosed |
| US-20080287458-A1 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | ROCHE PALO ALTO LLC | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | EGFR 3051/4885SMN1; SMN2 1042/4885ALDH1A1 4004/4885 |
| US-20110002952-A1 | FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kappaB ACTIVITY AND USE THEREOF | NFKB2, NFKBIA, AP1G1 | EGFR 3994/4885SMN1; SMN2 3957/4885ALDH1A1 2576/4885 |
| US-20170145026-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | EGFR 3051/4885SMN1; SMN2 1042/4885ALDH1A1 4004/4885 |
| US-20080287458-A1 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | MAPK9, MAPK10, MAPK1 | EGFR 163/4885SMN1; SMN2 3734/4885ALDH1A1 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.